Charles River Laboratories Intl. Inc vs VF Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $299.21 (market cap $14.23B), while VF Corp trades at $14.9 (market cap $5.71B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.5× VF Corp's market cap, and VF Corp pays a 2.48% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and VF Corp for 64 Days on average.
| CRL | VFC | |
|---|---|---|
Market Cap | $14.23B | $5.71B |
Volume | 1,176,885 | 8,987,330 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $21.55 |
52-Week Low | $149.93 | $12.62 |
Typical Hold Time | 33 Days | 64 Days |
Enterprise Value | $17.06B | $10.00B |
Dividend Yield | — | 2.48% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
VFC trades at $14.38, down 0.48% with a bullish technical signal from moving averages. The company shows mixed fundamentals with revenue declining from $11.8B in 2022 to $9.5B in 2025, while profitability remains challenged with negative net income of -$189.72M. Recent earnings show volatility with one beat and two misses in the last four quarters. The stock trades at attractive valuation multiples with P/E of 21.06 and P/S of 0.61, below industry averages.
VFC presents a turnaround opportunity with discounted valuation and improving cash flow projections for 2026, but faces significant execution risks from Vans brand weakness and ongoing debt reduction challenges. Analyst consensus leans neutral with 52% hold rating and $18.33 price target suggesting 27% upside potential, though recent dividend cuts and brand-specific headwinds require careful monitoring of Q3 earnings performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →